Alexander V Ratushny
Overview
Explore the profile of Alexander V Ratushny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sivakumar S, Jainarayanan A, Arbe-Barnes E, Sharma P, Ni Leathlobhair M, Amin S, et al.
Nat Commun
. 2025 Feb;
16(1):1397.
PMID: 39915477
Pancreatic ductal adenocarcinoma has a dismal prognosis. A comprehensive analysis of single-cell multi-omic data from matched tumour-infiltrated CD45+ cells and peripheral blood in 12 patients, and two published datasets, reveals...
2.
Brown L, Coles M, McConnell M, Ratushny A, Gaffney E
J Pharmacokinet Pharmacodyn
. 2022 Aug;
49(5):539-556.
PMID: 35933452
Physiologically-based pharmacokinetic and cellular kinetic models are used extensively to predict concentration profiles of drugs or adoptively transferred cells in patients and laboratory animals. Models are fit to data by...
3.
Abbiati R, Pourdehnad M, Carrancio S, Pierce D, Kasibhatla S, McConnell M, et al.
AAPS J
. 2022 Jan;
24(1):29.
PMID: 35038051
No abstract available.
4.
Gibbs D, Aguilar B, Thorsson V, Ratushny A, Shmulevich I
Front Genet
. 2021 Sep;
12:667382.
PMID: 34512714
The maintenance and function of tissues in health and disease depends on cell-cell communication. This work shows how high-level features, representing cell-cell communication, can be defined and used to associate...
5.
Abbiati R, Pourdehnad M, Carrancio S, Pierce D, Kasibhatla S, McConnell M, et al.
AAPS J
. 2021 Aug;
23(5):103.
PMID: 34453265
Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent...
6.
Wall M, Turkarslan S, Wu W, Danziger S, Reiss D, Mason M, et al.
NPJ Precis Oncol
. 2021 Jun;
5(1):60.
PMID: 34183722
Despite recent advancements in the treatment of multiple myeloma (MM), nearly all patients ultimately relapse and many become refractory to multiple lines of therapies. Therefore, we not only need the...
7.
Danziger S, McConnell M, Gockley J, Young M, Rosenthal A, Schmitz F, et al.
PLoS Med
. 2020 Nov;
17(11):e1003323.
PMID: 33147277
Background: The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone...
8.
Aguilar B, Gibbs D, Reiss D, McConnell M, Danziger S, Dervan A, et al.
Gigascience
. 2020 Jul;
9(7).
PMID: 32696951
Background: Mechanistic models, when combined with pertinent data, can improve our knowledge regarding important molecular and cellular mechanisms found in cancer. These models make the prediction of tissue-level response to...
9.
Danziger S, Gibbs D, Shmulevich I, McConnell M, Trotter M, Schmitz F, et al.
PLoS One
. 2019 Nov;
14(11):e0224693.
PMID: 31743345
Immune cell infiltration of tumors and the tumor microenvironment can be an important component for determining patient outcomes. For example, immune and stromal cell presence inferred by deconvolving patient gene...
10.
Holden J, Koreny L, Obado S, Ratushny A, Chen W, Bart J, et al.
Mol Biol Cell
. 2018 Mar;
29(9):1100-1110.
PMID: 29496964
Components of the nuclear periphery coordinate a multitude of activities, including macromolecular transport, cell-cycle progression, and chromatin organization. Nuclear pore complexes (NPCs) mediate nucleocytoplasmic transport, mRNA processing, and transcriptional regulation,...